Avascular necrosis of bone complicating corticosteroid replacement therapy

Osteonecrosis of Femoral Head is Associated with Congenital Multiple Pituitary Hormone Deficiency: Report of Three Cases and Literature Review

Objective: Pituitary hormones are critical for bone development and maturation. It is currently unknown whether congenital multiple pituitary hormone deficiency (CMPHD) is associated with osteonecrosis of femoral head (ONFH). Methods: Clinical presentations and hormonal profiles of three patients with CMPHD and ONFH were retrospectively described. The incidence of ONFH in this population was studied. Results: (1) Congenital hypopituitarism was diagnosed in three patients. Femoral epiphyseal fusion in these patients was markedly delayed, and they had very low bone mineral density. (2) Hip pain, which is the main presentation of ONFH, occurred at the age of 20-30 years. ONFH induced by excessive glucocorticoids was excluded. (3) The estimated incidence of ONFH was approximately 694:100,000. Conclusions: CMPHD, especially a lack of growth and sex hormones, may contribute to ONFH.

Possible Epidemiological Factors Associated with Rupture of the Posterior Tibial Tendon

Rupture of the posterior tibial tendon has been postulated to occur, in part, as a result of degenerative changes to the tendon. This possibility was examined by a review of 67 patients (average age 57 years) diagnosed with rupture of the posterior tibial tendon. Forty-five of the 67 patients (60%) had one or more of the following positive medical histories: (1) hypertension, (2) obesity, (3) diabetes mellitus, (4) previous surgery or trauma about the medial aspect of the foot, or (5) steroid exposure. Thirty-five patients (52%) had either hypertension, diabetes mellitus, or obesity. A statistical correlation was demonstrated between rupture of the posterior tibial tendon and obesity ( P = .005) and to a lesser extent hypertension ( P = .025). These disorders have been uniformly associated with an acceleration of the degenerative processes associated with aging, commonly via an acceleration of microvascular and macrovascular diseases. An additional vascular risk is implicated by the known zone of hypovascularity of the posterior tibial tendon and risk of rupture secondary to systemic or local injections of corticosteroids. The prevalence of posterior tibial tendon rupture parallels the degenerative processes of aging, hypertension, diabetes mellitus, and obesity. Additionally, the effects of corticosteroids and local surgical procedures may further be associated with local vascular impairment and eventual rupture.

Adverse Effects of Corticosteroids

Currently, adrenal corticosteroids (steroids) are used for a wide variety of clinical conditions. Steroids are known to cause many pathologic effects, including chemically induced diabetes, psychological changes, musculoskeletal (including avascular) necrosis, suppression of the adrenals, and significant effects on the eye. Considering the important risk factors involved with the use of these toxic, yet essential medications, pharmacists have a serious responsibility to monitor their use for indications, dosage, interactions, and side effects.

Osteonecrosis of the talus after talonavicular arthrodesis: a case report and review of the literature

Avascular necrosis of the talus is a well-documented complication following fractures, although less is known about this complication following reconstructive foot and ankle surgery. Knowledge of the blood supply of the talus is necessary for surgical dissection of the talus, especially when the approach traverses the sinus tarsi. In this article, we describe a rare case of avascular necrosis of the talus after talonavicular arthrodesis, using a medial surgical approach.

Steroid induced osteonecrosis: An analysis of steroid dosing risk

Osteonecrosis is a serious condition involving bone destruction that frequently requires surgical treatment to rebuild the joint. While there is an abundance of literature documenting corticosteroid related osteonecrosis, there is no consensus as to the relative risk of osteonecrosis after administration of steroids via parenteral, oral, topical, inhaled and other routes. This risk is an important prognostic indicator because identification and conservative intervention can potentially reduce morbidity associated with aggressive surgical treatment of osteonecrosis. This paper provides insight into establishing guidelines related to the risk of developing osteonecrosis as a result of corticosteroid use. Case studies, retrospective studies and prospective studies in humans on different corticosteroids and varied dosages were assessed. Most cases of osteonecrosis are secondary to systemically administered corticosteroids and/or high dose daily therapy, particularly in patients with underlying comorbidities including connective tissue diseases, hyperlipidemia, or previous trauma. Previous case reports of osteonecrosis related to inhaled or topical use of steroids are complicated by the fact that in the great majority of cases, the patients are also treated with systemic steroids prior to the development of osteonecrosis. Based on the literature, a set of recommendations regarding the risk of osteonecrosis in patients on steroids was formulated.

[Comorbidity of systemic lupus erythematosus]

Patients with systemic lupus erythematosus (SLE) suffer a series of incidence-associated pathologies more frequent than general population. Comorbility includes: infections, arteriosclerosis, coronary arteriopathy, osteoporosis, and avascular necrosis of the bone, to name the more frequent ones. In general, such complications are related, above all, to the degree of SLE activity and the dosages of daily and accumulated corticoids. It is a matter of highlighting the importance of the associated pathologies in regards to our patients' prognosis and of taking them into consideration when we establish a treatment for our patients' during each one of their visits.

Effect of systemic glucocorticoid therapy on bone metabolism: an update

Glucocorticoids are widely used for a range of inflammatory conditions. However, their use is complicated by significant side effects. The most important of these from a clinical point of view is on bone, where glucocorticoids substantially increase the risk of osteoporosis and fracture. This review will give an overview of the pathophysiologic basis and epidemiology of glucocorticoid-induced osteoporosis, examine diagnostic and therapeutic approaches currently available, and suggest the likely impact of the most recent scientific, clinical and pharmaceutical advances. Glucocorticoids impact on both bone formation and bone resorption, a combination that leads to rapid bone loss and increase in fracture risk. Epidemiologic studies indicate that these risks are substantial, especially at the spine, increase with age and independently of bone density, and are maintained during glucocorticoid use. The best available treatments are bisphosphonates that preserve bone density and reduce the risk of fracture at the spine. Future areas that need to be addressed are the relationship between inflammation and the action of glucocorticoids on the skeleton, and the development of anabolic therapies for glucocorticoid-induced osteoporosis.

Sensitivity of bone to glucocorticoids

Glucocorticoids are used widely in a range of medical specialities, but their main limitation is an adverse impact on bone. Although physicians are increasingly aware of these deleterious effects, the marked variation in susceptibility between individuals makes it difficult to predict who will develop skeletal complications with these drugs. Although the mechanisms underlying the adverse effects on bone remain unclear, the most important effect appears to be a rapid and substantial decrease in bone formation. This review will examine recent studies that quantify the risk of fracture with glucocorticoids, the mechanisms that underlie this increase in risk and the potential basis for differences in individual sensitivity. An important determinant of glucocorticoid sensitivity appears to be the presence of glucocorticoid-metabolizing enzymes within osteoblasts and this may enable improved estimates of risk and generate new approaches to the development of bone-sparing anti-inflammatory drugs.

Postpartum Multifocal Avascular Necrosis: What Are the Possible Etiologies?

Avascular necrosis of bone (osteonecrosis) that is atraumatic is most frequently associated with corticosteroid excess or alcoholism and usually involves the femoral head. We report a case of multifocal avascular necrosis in a 38-year-old woman with autoimmune Addison's disease taking corticosteroid replacement therapy. The onset of joint symptoms occurred 6 months after a pregnancy complicated by acute fatty liver and disseminated intravascular coagulation. Although both knees and ankles were involved, an unusual feature is that the hips were spared. As illustrated in this patient, avascular necrosis is frequently misdiagnosed in cases of joint pain of acute onset and may occur in the context of physiologic replacement doses of corticosteroids. Etiologic factors can precede the onset of symptoms and the diagnosis by several months.

Cushing's disease presenting with avascular necrosis of the hip: an orthopedic emergency

Nontraumatic avascular necrosis (AVN) of the hip is commonly caused by exogenous glucocorticoid administration, whereas it has rarely been associated with endogenous hypercortisolism. We report a 30-yr-old woman with Cushing's disease whose presenting manifestation was early AVN of the hip. Although plain x-ray was negative, magnetic resonance imaging (MRI) of the hip showed stage 2 AVN. Her orthopedic disease was considered an emergency, and thus, it was treated with core decompression before the diagnosis of Cushing's syndrome (CS) was pursued further. The femur recovered fully, as demonstrated by her improved clinical picture and a subsequent MRI. AVN carries a poor prognosis, if not treated early. The diagnostic procedure of choice is MRI, because plain radiographs are falsely negative in early stages. This case illustrates that AVN can be the presenting manifestation of CS; to prevent irreversible effects on the femoral head, core decompression should not be delayed for the purpose of evaluation and treatment of CS.

Total knee arthroplasty for steroid-induced osteonecrosis

There have been only a few reports that evaluate the outcome of total knee arthroplasty in patients with steroid-induced osteonecrosis of the knee. We retrospectively reviewed 31 total knee arthroplasties in 24 patients with confirmed steroid-induced osteonecrosis of the knee. The average follow-up was 64 months. Of surviving knees, 92% had significant improvement in knee scores. Five knees (16%) required a revision procedure. Reasons for revision were aseptic loosening in 3 knees and sepsis in 2 knees. Complications not requiring revision occurred in 6 of 31 knees (19%). Survivorship of total knee arthroplasty to revision in patients with steroid-induced avascular necrosis of the knee was 84% at 5 years. Although there was a slightly higher complication rate, this may, in part, be due to the severity of the patients' underlying disease processes. Total knee arthroplasty can be a successful procedure for chronically ill patients with steroid-induced osteonecrosis.

Avascular necrosis of bone following an intensified chemotherapy regimen including high dose steroids

We report the imaging findings and natural history of avascular necrosis of bone (AVN) that developed following a chemotherapy regimen including high dose steroid treatment. All patients had acute lymphoblastic (ALL) or non-Hodgkin's lymphoma (NHL). Symptoms followed the high dose steroid therapy and 28 joints in eight patients were involved, (11 knees, seven hips, five shoulders and five ankles). Plain radiographs at presentation were normal in most joints, whilst bone scintigraphy and magnetic resonance imaging (MRI) were positive. We believe that the development of AVN in these patients is most likely due to the high dose dexamethasone therapy as in all eight cases symptoms followed this stage of the regimen. Patients experiencing bone or joint pains while receiving high dose steroids as part of a chemotherapy regimen could be investigated by bone scintigraphy but MRI is preferable as it is more sensitive and specific for AVN. In this series of patients multiple joints were involved and all the male patients proceeded rapidly from bone infarction to joint collapse. If the MRI appearances are typical, an early diagnosis of AVN can be made enabling therapeutic interventions to prevent joint collapse and its associated morbidity.

Osteonecrosis of the femoral head in patients with inflammatory arthritis or asthma receiving corticosteroid therapy

The utilization of corticosteroids in the management of acute and chronic inflammatory processes, such as asthma or inflammatory arthritis, has been implicated in the adverse effects of multiple organ systems. One potential area of these negative consequences in the use of corticosteroids is the development of osteonecrosis of the femoral head. A direct time/dosage relationship for treatment with corticosteroids of patients with an established diagnosis of asthma or inflammatory arthritis and femoral osteonecrosis is unknown. A prospective study was undertaken to evaluate the use of corticosteroids and the incidence of osteonecrosis of the femoral head and potentially establish a time/dosage relationship in this patient population. No direct relationship between corticosteroid dosage and the development of femoral head osteonecrosis in 1420 hip-years was demonstrated at 10-year follow up.

Corticosteroid Misadventures

Misadventures and tragic events related to corticosteroids, some involving medical malpractice, some involving prescription errors, some involving illegal excessive refills of steroid prescriptions, and some the result of valid, legitimate steroid medication use, compel the pharmacist to continuous scrutiny and awareness of the serious toxicity related to corticosteroid medication. The pharmacist is encouraged to always pay special attention to the use, dose, frequency, duration, and effects of steroids. Good, complete pharmaceutical care will help limit toxicities associated with this important class of drugs, and thus limit the misadventures. This article provides the pharmacist reader with a review of the pharmacology, clinical uses, and adverse effects. Case discussions, both from the literature, and from litigation are presented, with appropriate discussion to demonstrate certain key information.

Osteonecrosis: current perspectives on pathogenesis and treatment

Nontraumatic osteonecrosis results from impairment of circulation to the affected bone. The femoral head is affected most frequently. The underlying cause for the circulatory defect in osteonecrosis varies and may involve both local and systemic changes. Steroid use, alcohol consumption, pancreatitis, and lipid disorders appear to lead to bone death either by development of fat emboli in the microcirculature surrounding the affected bone or by fatty infiltration of the marrow. Decompression syndrome results from the presence of gaseous emboli in the microcirculature. In Legg-Calvé-Perthes disease other associated features are present such as short stature, suboptimal growth velocity, and/or hormonal imbalances, and it is likely that osteonecrosis may be secondary to systemic abnormalities, although specific factors have not been identified. Other frequently suggested pathogenic factors that play a role in the development of osteonecrosis include increased intraosseous pressures, the presence of cytotoxic cellular factors, intravascular coagulation, venous stasis, and the hyperviscosity syndrome. Some investigators have attempted, without success, to find a common etiology for all cases of osteonecrosis. In addition, patients have developed osteonecrosis without any known risk factors; this syndrome has been coined idiopathic avascular necrosis. In advanced stages of femoral head osteonecrosis, total hip arthroplasty appears to be the best therapeutic modality, particularly in older individuals.

Drug-induced rheumatic syndromes. Diagnosis, clinical features and management

In order to avoid inappropriate therapy and prolonged morbidity, it is important to recognise when a patient's rheumatic complaints are due to drugs. However, this is often difficult because of the large number of drugs that have been implicated and the diversity of clinical presentations. Arthropathy may be seen with several different syndromes, including drug-induced lupus erythematosus (DILE), serum sickness and gout. The most widely reported of these is DILE, which usually develops after some months or even years of drug therapy. While many authors do not specifically require their presence for the diagnosis of DILE, antinuclear antibodies have been detected in the great majority of reported patients with DILE, whatever the causative drug. In contrast, patients who develop arthropathy soon after commencing a drug rarely have antinuclear antibodies and appear to be distinct from patients with DILE. Apart from arthropathy, a number of other syndromes that appear to have an immunological basis may be induced by drugs. Cutaneous vasculitis is not uncommon and drugs are frequently considered to be the aetiological factor. Whether drugs may cause larger vessel systemic vasculitis is less certain. Rarely, polymyositis and scleroderma-like syndromes have been associated with drug therapy. Corticosteroid-induced osteoporosis is a complication of all the corticosteroid preparations that are widely used at present. However, the development of deflazacort, a so-called 'bone-sparing' steroid, has raised the possibility that the effect of corticosteroids on bone may be separable, at least in part, from the other actions of these drugs. Data have been conflicting with regard to whether there is a 'safe' dose of corticosteroid. Similarly, it is unclear whether prophylactic therapy with agents such as calcium, fluoride and vitamin D is beneficial. Nonetheless, recent findings suggest that approaches will be developed to minimise the risk of osteoporosis in patients who require corticosteroids. There are a number of other ways in which drugs may affect bones. Osteomalacia is a well-known but uncommon complication of treatment with anticonvulsants and occasionally other drugs. The mechanism probably relates to the induction of hepatic enzymes and the consequent increased metabolism of vitamin D in patients with borderline levels initially. Osteosclerosis may also result from drug therapy; usually with fluoride or retinol (vitamin A) and its analogues. With continued research, the true spectrum of drug-induced rheumatic syndromes should become more clearly defined.(ABSTRACT TRUNCATED AT 400 WORDS)

Cushing's disease presenting with avascular necrosis of the femoral heads and complicated by pituitary apoplexy

A case of Cushing's disease presenting with avascular necrosis of the femoral heads is described. Eighteen months after the onset of hip symptoms the patient developed pituitary apoplexy and presented to hospital as a medical emergency. Endogenous hypercortisolism is a rare and important cause of avascular necrosis of bone.

Early treatment of avascular necrosis in systemic lupus erythematosus

Avascular necrosis (AVN) of the hips is associated with significant disability, and the majority of established cases require major surgery. In a retrospective analysis of 185 patients with systemic lupus erythematosus (SLE) 13 (7%) were found to have AVN. Of these, six had Raynaud's phenomenon, all had been on corticosteroids, and one had digital vasculitis. The mean duration of corticosteroid therapy was two years (range four months to five years). Five patients developed AVN two to 10 years after discontinuing steroids. The mean duration of disease at the onset of AVN was 6.85 years (range 1-19 years), and the mean age at onset of AVN was 31 years. Ten patients had severe multisystem involvement. None of the patients abused alcohol. Surgery was performed on 11 hips. Three had total hip replacement for stages 3 and 4 and seven had core decompression for stages 1 and 2. AVN progressed in two (28%) of these patients. In another patient core decompression failed for technical reasons. She subsequently required total hip replacement. The early detection of AVN to avoid the need for major surgery is stressed.

Avascular necrosis of bone following short-term dexamethasone therapy for brain edema. Case report

The authors present a case of avascular necrosis of both femoral and humeral heads which developed after short-term steroid treatment for brain edema. A vascular necrosis of bone may develop after short-term as well as after maintenance steroid therapy. Early diagnosis with bone scanning and management may in some cases prevent joint destruction.

[Aseptic necrosis of the femoral head in young adults]

Aseptic necrosis of the femoral head is a well-defined entity. The underlying diseases originate from very different types of pathological conditions. Alcoholism, cortisone therapy, gout or hyperuricemia, sickle cell anaemia and others all lead, through various pathways, to the impairment of the medullary blood flow. In many instances, a compartment syndrome can be demonstrated in the femoral head. Death of the osteocytes follows bone marrow necrosis. Revascularisation originates in the periphery of the necrotic segment. Vascular buds and fibroblasts invade the medullary space. New bone is laid over the necrotic trabeculae. Mechanical failure results from changes in the bony framework at three different levels. The subchondral boneplate may be weakened by the process of revascularisation, the necrotic trabeculae may fail because of diminished stiffness and strength, and overloading has been demonstrated at the junction between dead and living bone. Elevation of the intramedullary pressure is the first objective sign of impending or established bone necrosis. Scintigraphy with Technetium 99 m - Sulphur colloid can now show the early stages of marrow necrosis. Roentgenographic changes only appear in a later phase of the disease. Aseptic necrosis must be considered as involving both hips, unless proven otherwise. Attention given to the "silent hip" may allow salvage and prevent the occurrence of osteo-arthritic changes leaving merely unilateral disease. As long as the geometrical shape of the femoral head is maintained operation may well prove useful. The aim at this stage is to prevent collapse. It is impossible to know in the early stages whether mechanical failure will occur, but there is general agreement that the femoral head will eventually undergo deformation. A spherical epiphysis is therefore considered a success. All the conservative methods aim to decompress the medullary cavity. Core biopsy, curettage, bone grafting and intertrochanteric osteotomy all have their advocates. After fracture of the subchondral bone plate has occurred, there is evidence that grafts are unable to restore the strength of the necrotic area. Intertrochanteric osteotomy brings under the main load-bearing zone a vital part of the femoral head. Varus osteotomy can be successful if necrosis has spared sufficient of the lateral portion of the head. Rotation osteotomies, as proposed by Sugioka, are more radical and difficult operations. The published results are promising. Revascularisation of the weight-bearing area by pedicle grafts has been attempted, alone or in addition to osteotomy.(ABSTRACT TRUNCATED AT 400 WORDS)